Fadi George Towfic

Title: Fadi George Towfic: Innovator in Lymphoma Classification

Introduction

Fadi George Towfic is a notable inventor based in Madison, NJ (US). He has made significant contributions to the field of oncology, particularly in the classification of diffuse large B-cell lymphoma (DLBCL). His innovative methods have the potential to improve patient outcomes through more accurate diagnoses.

Latest Patents

Fadi George Towfic holds a patent for "Methods of classifying diffuse large B-cell lymphoma." This patent describes a method for predicting whether a subject has an Activated B Cell-like (ABC) subtype or a non-ABC subtype of DLBCL. The process involves obtaining a sample from the subject, measuring the expression levels of CD10, MUM1, FOXP1, and optionally Bcl-6. A composite score is then determined based on these expression levels, which aids in predicting the subtype of DLBCL.

Career Highlights

Fadi is currently employed at Celgene Corporation, where he continues to work on innovative solutions in the field of cancer research. His expertise and dedication to improving diagnostic methods have made him a valuable asset to his team.

Collaborations

Fadi collaborates with talented colleagues, including Yixin Wang and Sarah Hersey. Their combined efforts contribute to advancing research and developing new methodologies in oncology.

Conclusion

Fadi George Towfic's work in lymphoma classification exemplifies the impact of innovation in medical research. His contributions are paving the way for improved diagnostic techniques that can enhance patient care.